Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn
Drugmaker’s potential acquisition of Ollin Biosciences is latest in glut of deals in biotechnology sector
Drugmaker’s potential acquisition of Ollin Biosciences is latest in glut of deals in biotechnology sector